• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

SERCHING FOR AN IDEAL HRT-USE OF PROGESTERONE VAGINAL SUPPOSITORIES IN COMBINATION WITH SYSTENIC ESTROGEN ADMINISTRATION

Research Project

Project/Area Number 10671564
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionKyoto Prefectural University of Medicine

Principal Investigator

HIDEO Honjo  Kyoto Prefect. Univ. of Med., Ob/Gyn, Professor, 医学部, 教授 (30110852)

Co-Investigator(Kenkyū-buntansha) K Tanka  Kyoto Prefect. Univ. of Med., Ob/Gyn, Assistant, 医学部, 助手 (40295671)
Project Period (FY) 1998 – 1999
Project Status Completed (Fiscal Year 1999)
Budget Amount *help
¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 1999: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1998: ¥3,300,000 (Direct Cost: ¥3,300,000)
Keywordsprogesterone / vaginal suppository / hormone replacement therapy / Alzheimer's disease / depressive state / endometrial cancer / genital bleeding / 性器出血 / ホルモン補充療法 / 黄体ホルモン / エストロゲン
Research Abstract

HRT(hormone replacement therapy) has prevailed worldwide among climacteric and elderly women. However, progestogen, when administered systemically in combination with estrogen, sometimes make patients' mood depressive. In this study, we prepared progesterone vaginal suppositories and examined their efficacy.
A : Making vaginal suppositories. H-15 : progesterone(ampule) 50mg+Witepsol H15 : 1.2g. E-85 : same 50mg+Witepsol E-85 : 1.32g. RE : progesterone(reagent) 50mg+H15 : 1.2g.
B : Single administration : To 13 patients receiving hysterectomy, a PVS was administered before operation (H-15 : 2, E-85 : 7, TE : 4). Serum progesterone was measured before, and after administration, and myometrial and endometrial progesterone concentrations were also measured. Serum progesterone level was highest at 2 or 4 hours after administration, and lowered ed to basal level at 24 hours. In these patients, myometrial and endometrial progesterone level were 12.0【plus-minus】15.5ng/g(range : 2-54), and 26.6【p … More lus-minus】25.5(range : 2.5-230) which were 0.67-5.93 and 0.53-17.5(average : 5.9) folds of the maximal serum level, respectively.
C : Administration in HRT : PVSs were administered to 17 patients in HRT. To 16 patients PVSs were administered cyclically (basically 10 days in a cycle, 68cycles), H-15 was used only in 4 cycles (4 patients) because all of the patients claimed inconvenience (too soft). E-85 (25 cycles, 12 patients) was hard enough. RE (45 cycles, 10 patients) was easiest to use. Withdrawal bleeding (WDB) was analyzed in 68 cycles of cyclic administration. Bleeding did not occur in three cycles of RE. In 25 cycles WDB started before finishing the ten suppositories. In the rest 40 cycles, WDB started 1 to 8 days after cessation of PVS. Duration of bleeding was 4【plus-minus】1 days, amount of bleeding was moderate in most cycles. In some cycles, progesterone effect was confirmed with ultra sonogram and/or histological examination of the endometrium. Vaginal discharge and genital discomfort were complained in most of H-15 cycles and some E-85 cycles. Depressive mood was infrequent. Less

Report

(3 results)
  • 1999 Annual Research Report   Final Research Report Summary
  • 1998 Annual Research Report
  • Research Products

    (10 results)

All Other

All Publications (10 results)

  • [Publications] 本庄英雄、田中一範: "新しい治療・閉経後女性の健康管理における新しい薬物療法の展望"治療学. 32・11. 1442-1445 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] K, Tanaka, Honjo et al.: "PROGESTERONE VAGINAL SUPPOSITORY IN HORMONE REPLA CEMENT THERAPY"Adv Obstet Gynecol. 52・2. 335-339 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] H. Honjo, K. Tanaka et al.,.: "Further Basic and Clinical Investigations for Alzheimer's disease, The Menopause at the Millennium"Parthenon Publishing, UK. (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] H. Honjo, K. Tanaka.: "A review of medications of postmenopausal women"Biomedicine and Therapeutics. 32(11). 1442-1445 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] K. Tanaka, H. Tatsumi, T. Hosoda, H. Honjo et al.: "PROGESTERONE VAGINAL SUPPOSITORY IN HORMONE REPLACEMENT THERAPY"Adv Obstet Gynecol. 52(2). 335-339 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] H. Honjo, K. Tanaka et al.: "Further Basic and Clinical Investigations for Alzheimer's disease, The Menopause at the Millennium (proceeding of the 9th International Menopause Society World Congress on the Menopause)"The Menopause at the Millennium (proceeding of the 9th International Menopause Society World Congress on the Menopause), Parthenon Publishing, UK. (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] 本庄英雄、田中一範: "新しい治療-閉経後女性の健康管理における新しい薬物療法の展望"治療学. 32・11. 1442-1445 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] K.Tanaka,H.Honjo et al.: "PROGESTERONE VAGINAL SUPPOSITORY IN HORMONE REPLACEMENT THERAPY"Adv Obstet Gynecol. 52・2. 335-339 (2000)

    • Related Report
      1999 Annual Research Report
  • [Publications] H.Honjo,K.Tanaka et al.,: "Further Basic and Clinical Investigations for Alzheimer's disease,The Menopause at the Millennium"Parthenon Publishing,UK. (2000)

    • Related Report
      1999 Annual Research Report
  • [Publications] 本庄英雄ほか: "新しい治療-閉経後の女性の健康管理における新しい薬物療法の展望" ライフサイエンス出版,治療学. 32・11. 1442-1445 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1998-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi